News - Pfizer, Xeljanz


Current filters:


Popular Filters

Systemic psoriasis market forecast to reach $10.4 billion by 2020


The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib


Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Disappointment for Pfizer on negative CHMP view for Xeljanz


There was disappointment for US pharma behemoth Pfizer (NNYSE: PFE), when the European Medicines Agency's…


Pfizer gets Swiss nod for Xeljanz for rheumatoid arthritis


US drug giant Pfizer (NYSE: PFE) said its rheumatoid arthritis (RA) therapy Xeljanz (tofacitinib) has…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationTakeda NycomedXeljanz

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

EMA committee gives thumbs down for Pfizer's Xeljanz for RA


Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…


US Senator calls for re-examination of pricing of drugs developed with public funds


US Senator Ron Wyden (Democrat, Oregon) has released a letter written to National Institutes of Health…

North AmericaPfizerPharmaceuticalPoliticsPricingResearchXeljanz

Newly approved tofacitinib slows rheumatoid arthritis joint damage


A Phase III clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression…


FDA approves Pfizer's Xeljanz for rheumatoid arthritis


Having in the summer put back its "action date" due to a request for additional analysis of the existing…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinibXeljanz

Back to top